The hub plans to build on the existing partnership with UH and Baylor, as well as other clinical and research groups within the Texas Medical Center. Photo via Getty Images

The University of Houston and Baylor College of Medicine have been awarded a sizable grant to create a regional research hub.

The National Center for Advancing Translational Research awarded the $44.2 million Clinical and Translational Science Award Program grant to the two schools, which will work to create a regional hub called the Consortium for Translational and Precision Health. CTPH will “serve as a support for infrastructure, services, community engagement and workforce development to advance research and drive innovation in clinical translational science,” per a UH news release.

The hub plans to build on the existing partnership with UH and Baylor, as well as other clinical and research groups within the Texas Medical Center. CTPH aims to connect regional investigators with community healthcare organizations and government agencies that contribute to clinical research, healthcare, and policy. The new hub plans to provide funding for projects in pilot, and support ongoing research to help “accelerate the pace of research from discovery to population level impact,” according to the release. Over 60 leading medical institutions receive CTSA Program funding.

“Research is the engine empowering health care’s life-changing advancements,” UH President Renu Khator says in a news release. “This innovative hub will be a catalyst for groundbreaking discoveries and treatments that improve people’s quality of life. That’s what drives us at UH and we’re ecstatic to cofound a regional hub for change alongside Baylor.”

Leading the program will be Dr. Christopher Amos, professor and director of the Institute for Clinical and Translational Research (ICTR) at BCM; Dr. Fasiha Kanwal, professor of medicine and chief of the section of gastroenterology and hepatology at BCM; and Dr. Bettina M. Beech, clinical professor of population health and the chief population health officer at UH.

The CTPH will also work with Tilman J. Fertitta Family College of Medicine, Andy & Barbara Gessner College of Nursing, College of Pharmacy, College of Optometry, C. T. Bauer College of Business, Cullen College of Engineering, College of Natural Sciences and Mathematics, College of Education, College of Liberal Arts and Social Sciences, and the Honors College — all UH colleges.

“We are deeply committed to advancing innovation in clinical and translational science, and this award is a significant step forward in our mission to improve population health outcomes,” Beech says in a news release. “This is a testament to the unwavering dedication and collaborative spirit of everyone involved. It truly was a team effort.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”